Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the initiation of a Phase 2 ...
Autobahn Therapeutics raised $100 million in a Series C this week, pledging to use the new funding for its pipeline of drug candidates for depression and other central nervous system disorders.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback